Cost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom.

2.50
Hdl Handle:
http://hdl.handle.net/11287/620355
Title:
Cost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom.
Authors:
Muthukumar, M.; Desai, K.; Abogunrin, S.; Harrower, Timothy; Gabriel, S.; Dinet, J.
Abstract:
Cervical dystonia (CD) involves painful involuntary contraction of the neck and shoulder muscles and abnormal posture in middle-aged adults. Botulinum neurotoxin type A (BoNT-A) is effective in treating CD but little is known about its associated cost-effectiveness.
Citation:
Cost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom. 2017, 9:211-229 Clinicoecon Outcomes Res
Publisher:
Dove Press
Journal:
ClinicoEconomics and outcomes research : CEOR
Issue Date:
15-Apr-2017
URI:
http://hdl.handle.net/11287/620355
DOI:
10.2147/CEOR.S112254
PubMed ID:
28458568
Additional Links:
https://dx.doi.org/10.2147/CEOR.S112254
Note:
This article is freely available via Open Access. Click on the Additional Link above to access the full-text via the publisher's site.
Type:
Journal Article
Language:
en
Appears in Collections:
Neurology; 2017 RD&E publications

Full metadata record

DC FieldValue Language
dc.contributor.authorMuthukumar, M.en
dc.contributor.authorDesai, K.en
dc.contributor.authorAbogunrin, S.en
dc.contributor.authorHarrower, Timothyen
dc.contributor.authorGabriel, S.en
dc.contributor.authorDinet, J.en
dc.date.accessioned2017-06-13T13:00:19Z-
dc.date.available2017-06-13T13:00:19Z-
dc.date.issued2017-04-15-
dc.identifier.citationCost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom. 2017, 9:211-229 Clinicoecon Outcomes Resen
dc.identifier.pmid28458568-
dc.identifier.doi10.2147/CEOR.S112254-
dc.identifier.urihttp://hdl.handle.net/11287/620355-
dc.description.abstractCervical dystonia (CD) involves painful involuntary contraction of the neck and shoulder muscles and abnormal posture in middle-aged adults. Botulinum neurotoxin type A (BoNT-A) is effective in treating CD but little is known about its associated cost-effectiveness.en
dc.language.isoenen
dc.publisherDove Pressen
dc.relation.urlhttps://dx.doi.org/10.2147/CEOR.S112254en
dc.rightsArchived with thanks to ClinicoEconomics and outcomes research : CEOR. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.en
dc.subjectWessex Classification Subject Headings::Neurologyen
dc.titleCost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom.en
dc.typeJournal Articleen
dc.identifier.journalClinicoEconomics and outcomes research : CEORen
dc.description.noteThis article is freely available via Open Access. Click on the Additional Link above to access the full-text via the publisher's site.en
dc.type.versionPublisheden

Related articles on PubMed

All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.